GIPL Research | Milton Maxwell

GIPL

Global Innovative Platforms Inc.

0.1110

+0.0000+0%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

69.00K

P/E (TTM)

Basic EPS (TTM)

-46.28

Dividend Yield

Recent Filings

8-K

11/24/25Nov 24, 2025

8-K

VOCAM deal, auditor switch

11/7/25Nov 7, 2025

Global Innovative Platforms inked a deal on November 2, 2025, with a global animal health firm to supply VOCAM Plus diagnostic units for canine heartworm detection evaluation. Days later, on November 3, it dismissed auditor MSMR—clean break, no disagreements—and tapped CNGSN as replacement. Smooth audit switch. This partnership validates breathomics tech amid accounting housekeeping.

8-K

Updated investor presentation posted

9/26/25Sep 26, 2025

Global Innovative Platforms Inc. posted an updated investor presentation on its website on September 26, 2025, under Item 7.01 Regulation FD. The deck, furnished as Exhibit 99.1, is now live at www.vetbreath.com in Investor Relations. Not filed; furnished only.

10-Q

Q3 FY2025 results

8/20/25Aug 20, 2025

Global Innovative Platforms posted no revenue for Q3 FY2025 ended June 30, 2025, with operating loss widening to $211,818 from $6,360 y/y, driven by $50,000 license fees, $87,756 executive compensation, and $54,110 offering costs tied to its May registration statement; nine-month loss hit $483,635, up from $59,715 y/y (derived). Cash climbed to $198K from $15 at FY start, fueled by $694K stock sales offsetting $496K operating burn—no FCF as capex absent. Related-party loan fell to $25K. Team expanded; VOCAM unit acquired post-quarter. Material weakness persists in controls. Going concern looms large.

8-K

Updated investor presentation posted

6/23/25Jun 23, 2025

Global Innovative Platforms Inc. posted an updated investor presentation on its website on June 23, 2025, under Item 7.01 Regulation FD. The deck, furnished as Exhibit 99.1, is available at www.vetbreath.com in Investor Relations. Not filed; furnished only.

About

Global Innovative Platforms Inc. engages in the business of testing breath to detect and assist in the treatment of disease. The company develops Heartworm breath test, which includes breath sampler and collection kit. It also operates VOCAM Plus and FROG platform for gas chromatography, as well as operates A.I. software to provide breath and air analysis. The company was formerly known as Canning Str Corp. and changed its name to Global Innovative Platforms Inc. in September 2021. Global Innovative Platforms Inc. was incorporated in 2020 and is based in Orlando, Florida.

CEO

Mr. Andrew Brown

IPO

12/23/2003

Employees

Sector

Financial Services

Industry

Shell Companies